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by Elsevier B.V. All rights reserved.Hepatocellular carcinoma (HCC) occurs in more than 90% of cases
in patients with cirrhosis. As only small tumours are eligible for
curative treatment (radiofrequency, resection, transplantation),
surveillance in cirrhotic patients is recommended by European
and American societies [1,2]. Surveillance is usually based on
liver ultrasonographic examination (US) and serum alpha-
fetoprotein (AFP) assay on a semi-annual basis [1,2].
All patients with cirrhosis are candidates for surveillance
regardless of the cause of the underlying liver disease [1]. Never-
theless, curative treatment of HCC being the main objective, sur-
veillance is not recommended in patients with decompensated
cirrhosis (usually not eligible for resection or radiofrequency)
when transplantation is impossible [3]. Concerning the modali-
ties of surveillance, there is a large consensus that US is the most
prevalent and reliable tool and that serum AFP is not so useful
due to the high rate of false-negative and -positive results [4].
Surveillance periodicity has been established on an empirical
basis [1]. Recent studies suggest that a 6-month interval is supe-
rior to a 12-month interval [5] and not inferior to a 3-month
interval at least with the relatively low sensitivity of current
diagnostic procedures [6].
The clinical beneﬁt of surveillance is controversial. The only
randomized trial comparing surveillance with no surveillance
has been performed in China in a large number of patients with
HBV infection (cirrhotic or not) and a lower mortality in surveil-
lance group (37%) was demonstrated in spite of relatively low
compliance [7]. To perform a new randomized trial including a
non surveillance group seems unrealistic. In a recent attempt,
84% of the 192 informed patients chose surveillance andJournal of Hepatology 20
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that surveillance of cirrhotic patients is an effective procedure.
While the rate of small HCC is less than 20% without surveillance,
it is close to 70% in surveillance programs in the more recent
studies [9]. Consequently the percentage of patients eligible for
curative treatments has markedly risen. A study from Hong Kong
[9] reports better survival among patients who underwent sur-
veillance in the period 1998–2004 than those in 1991–1997,
likely due to higher rate of curative treatment. Another study
from France [10] reports better survival in patients treated during
1996–2005 than during 1976–1985, when surveillance was
rarely performed and modern curative treatments were not avail-
able. Moreover, recent studies taking into account modern cura-
tive treatments have concluded that surveillance is cost-effective
[11,12].
If surveillance is really effective, a large implementation at a
population scale should result in a signiﬁcant improvement in
the survival of cirrhotic patients who develop HCC. However such
an improvement has not been reported so far. The recent study
from the United States by Davila et al. [13] suggests that imple-
mentation of surveillance in cirrhotic patients is inadequate in
real life. The study included 1873 patients with HCC and previ-
ously diagnosed cirrhosis, recruited during 1994–2002 from
Medicare databases. All patients were over 65 years of age. The
main result was that regular surveillance (annual AFP and/or
US test during at least 2 of the 3 years prior to HCC diagnosis)
was performed in only 17% of patients before HCC diagnosis.
Moreover, US was performed in only 54% of patients who under-
went surveillance, serum AFP assay being the single test used in
the remaining 46% of patients. Patients belonging to Child–Pugh
class C had a higher rate of regular surveillance than patients
belonging to classes A and B (22% versus 15%). The most impor-
tant factors linked to surveillance were practice and afﬁliation
of physicians and some demographic characteristics of patients
such as income and education. Chances of beneﬁtting from regu-
lar surveillance were higher when patients were followed-up by a
gastroenterologist/hepatologist by comparison with an internal
medicine/primary care physician, or by a physician with aca-
demic afﬁliation by comparison with solo practice (4.5- and
3.7-fold, respectively). As emphasized by authors, some bias
could affect the results of the study. In particular it was not pos-
sible to identify precisely the tests (US and serum AFP) performed
in surveillance intent. Using data extracted from medical records11 vol. 54 j 1310–1311
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in two hospitals, the authors built an algorithm using a set of
variables that were able to predict whether serum AFP or US were
performed for surveillance. However, even when all US and AFP
tests were counted as surveillance (irrespective of intent), the
rate of regular surveillance increased to only 35%. Moreover,
the deﬁnition of regular surveillance was not very stringent by
comparison with ofﬁcial recommendations. Considering that
serum AFP was the sole test in half of the 17% of patients submit-
ted to regular surveillance, less than 10% of patients with cirrho-
sis have been followed-up according to current standards.
What is the cause of those very disappointing results? For
data being extracted from Medicare databases, only patients over
65 years were concerned and it is not possible to rule out that
surveillance was more effectively implemented in younger
patients. Physicians may consider that ‘‘elderly’’ are not eligible
for curative treatments (even if some recent studies suggest the
opposite [14,15]) or younger patients could be more prone to
search medical information (via the internet for instance). The
study by Davila et al. strongly suggests that information provided
to physicians and patients is a major factor favouring surveillance
in cirrhotic patients. Gastroenterologists/hepatologists and phy-
sicians afﬁliated to a medical school, who were credited with
the best rates of regular surveillance (26% and 30%, respectively),
are likely better informed about ofﬁcial recommendations and
consequently more prone to promote surveillance among their
patients. In a survey performed in 1999 [16], 96% of specialists
in the United States declared performance of surveillance in cir-
rhotic patients. Similarly, patients living in areas with higher
incomes and high rates of school education (presumably linked
to better access to medical information) had the highest percent-
ages of regular surveillance (19% and 21%, respectively) com-
pared to other patients. However, due to the design of the
study (only the tests that were really performed were recorded),
important information is lacking about the respective role of phy-
sicians’ recommendations and patient compliance to them. The
only optimistic result is a progressive increase in regular surveil-
lance rates, from 9% in 1994–1996 to 21% in 2000–2002, coinci-
ding with the publication of the ﬁrst EASL recommendations [2].
In conclusion, this study emphasizes that development and
publication of ofﬁcial recommendations are not sufﬁcient to pro-
mote their implementation at a population scale. A huge effort is
needed to extend recommendations concerning the surveillance
of patients with cirrhosis to primary care physicians and also to
improve the adherence of patients. Academic studies must be
performed in order to demonstrate convincing beneﬁts that to
promote surveillance among physicians and patients. Further
studies are needed in order to determine whether the situation
is similar in other countries where surveillance is recommended
and also to identify the factors that improve adherence to recom-
mendations concerning surveillance.Journal of Hepatology 2011Conﬂict of interest
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